Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15621612 | 0.86 | HDAC4 (0.43) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL256776 | 0.82 | HDAC4 (0.44) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL12203839 | 0.82 | HDAC4 (0.49) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL3115885 | 0.81 | OPRM1 (0.51) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL9393626 | 0.78 | HDAC4 (0.39) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL10820262 | 0.77 | SIGMAR1 (0.41) | HDAC4OPRM1 | |
| SCHEMBL6926820 | 0.76 | OPRD1 (0.44) | HDAC4OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL6926217 | 0.72 | OPRM1 (0.42) | OPRL1OPRM1OPRD1OPRK1HSD11B1 | |
| SCHEMBL1366868 | 0.71 | OPRL1 (0.41) | OPRL1OPRM1OPRD1OPRK1BACE1 | |
| SCHEMBL12475301 | 0.70 | BACE1 (0.39) | HDAC4OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062277-A1 | PHOSPHODIESTERASE 10 INHIBITORS | PDE5A, PDE12, PDE10A | HDAC4 100/4885OPRL1 1140/4885OPRM1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.